Antimicrobial susceptibilities of commonly encountered bacterial isolates to fosfomycin determined by agar dilution and disk diffusion methods

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 9, 2011, Pages 4295-4301

  Lu, Ching Lan ^a   Liu, Chia Ying ^b   Huang, Yu Tsung ^a,b   Liao, Chun Hsing ^b   Teng, Lee Jene ^a,c   Turnidge, John D ^d,e   Hsueh, Po Ren ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d SA PATHOLOGY   (Australia)

^e UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

FOSFOMYCIN; VANCOMYCIN;

ACINETOBACTER BAUMANNII; AGAR DILUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; DISK DIFFUSION; ENTEROBACTER CLOACAE; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; IN VITRO STUDY; INHIBITION KINETICS; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SEROPREVALENCE; STENOTROPHOMONAS MALTOPHILIA; URINARY TRACT INFECTION; WILD TYPE;

ACINETOBACTER BAUMANNII; ANTI-BACTERIAL AGENTS; ENTEROBACTERIACEAE; ENTEROCOCCUS FAECALIS; FOSFOMYCIN; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS;

EID: 80051823600     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00349-11     Document Type: Article

References (41)

1. Allerberger, F, and I. Klare. 1999. In-vitro activity of fosfomycin against vancomycin-resistant enterococci. J. Antimicrob. Chemother. 43:211-217. (Pubitemid 29082445)
2. Barry, A L, and P C Fuchs. 1991. In vitro susceptibility testing procedures for fosfomycin tromethamine. Antimicrob. Agents Chemother. 35:1235-1238.
3. Barry, A L, and S D Brown. 1995. Antibacterial spectrum of fosfomycin trometamol. J. Antimicrob. Chemother. 35:228-230.
4. British Society for Antimicrobial Chemotherapy. 2010. BSAC methods for antimicrobial susceptibility testing. British Society for Antimicrobial Chemotherapy, Birmingham, United Kingdom. http://www.bsac.org.uk/Resources/BSAC/ Version-9.1-March-2010-final%20v2.pdf. Accessed 10 March 2011.
5. Clinical and Laboratory Standards Institute. 2009. Performance standards for antimicrobial disk susceptibility tests; approved standard M2-A10, 10th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
6. Clinical and Laboratory Standards Institute. 2009. Methods for dilution susceptibility tests for bacteria that grow aerobically; approved standard. M7-A8, 8th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
7. Clinical and Laboratory Standards Institute. 2011. Performance standards for antimicrobial susceptibility testing; 20th informational supplement. CLSI document M100-S21. Clinical and Laboratory Standards Institute, Wayne, Pa.
8. Clinical and Laboratory Standards Institute/NCCLS. 2001. Development of in vitro susceptibility testing criteria and quality control parameters; approved guideline, 2nd ed. NCCLS document M23-A2. National Committee for Clinical Laboratory Standards, Wayne, PA.
9. Comité De l'Antibiogramme de la Société Française de Microbiologie. 2010. Comite de l'Antibiogramme de la Société Française de Microbiologie Recommandations 2010 (edition de Janvier 2010). http://www.sfm-microbiologie.org/UserFiles/file/ casfm-2010.pdf. Accessed 10 March 2011. (In French.)
10. Crocchiolo, P. 1990. Single-dose fosfomycin trometamol versus multipledose cotrimoxazole in the treatment of lower urinary tract infections in general practice. Multicenter Group of General Practitioners. Chemotherapy 36(Suppl. 1):37-40.
11. De Cueto, M., L. Lopez, J R Hernandez, C. Morillo, and A. Pascual. 2006. In vitro activity of fosfomycin against extended-spectrum beta- lactamaseproducing Escherichia coli and Klebsiella pneumoniae: Comparison of susceptibility testing procedures. Antimicrob. Agents Chemother. 50:368-370. (Pubitemid 43042949)
12. De Jong, Z., F. Pontonnier, and P. Plante. 1991. Single-dose fosfomycin trometamol (Monuril) versus multiple-dose norfloxacin: Results of a multicenter study in females with uncomplicated lower urinary tract infections. Urol. Int. 46:344-348.
13. Endimiani, A., et al. 2010. In vitro activity of fosfomycin against blaKPC-producing Klebsiella pneumoniae isolates, including those nonsusceptible to tigecycline and/or colistin. Antimicrob. Agents Chemother. 54:526-529.
14. European Committee on Antimicrobial Susceptibility Testing. 13 December 2009. European Committee on Antimicrobial Susceptibility Testing. http://www.eucast.org. Accessed 20 June 2010.
15. Falagas, M E, K P Giannopoulou, G N Kokolakis, and P I Rafailidis. 2008. Fosfomycin: Use beyond urinary tract and gastrointestinal infections. Clin. Infect. Dis. 46:1069-1077. (Pubitemid 351589875)
16. Falagas, M E, et al. 2008. Antimicrobial susceptibility of multidrug-resistant Gram negative bacteria to fosfomycin. Eur. J. Clin. Microbiol. Infect. Dis. 27:439-443. (Pubitemid 351713066)
17. Falagas, M E, A C Kastoris, D E Karageorgopoulos, and P I Rafailidis. 2009. Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gram-negative bacilli: A systematic review of microbiological, animal and clinical studies. Int. J. Antimicrob. Agents 34:111-120.
18. Falagas, M E, et al. 2009. Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycin. Int. J. Antimicrob. Agents 35:240-243.
19. Falagas, M E, N. Roussos, I D Gkegkes, P I Rafailidis, and D E Karageorgopoulos. 2009. Fosfomycin for the treatment of infections caused by Gram-positive cocci with advanced antimicrobial drug resistance: A review of microbiological, animal and clinical studies. Expert Opin. Invest. Drugs 18:921-944.
20. Fuchs, P C, A L Barry, and S D Brown. 1999. Fosfomycin tromethamine susceptibility of outpatient urine isolates of Escherichia coli and Enterococcusfaecalis from ten North American medical centres by three methods. J. Antimicrob. Chemother. 43:137-140. (Pubitemid 29045943)
21. García-Rodríguez, J A, et al. 1997. In vitro activity of fosfomycin trometamol against pathogens from urinary tract infections: A Spanish multicenter study. J. Chemother. 9:394-402. (Pubitemid 28012790)
22. Jean, S S, L J Teng, P R Hsueh, S W Ho, and K T Luh. 2002. Antimicrobial susceptibilities among clinical isolates of extended-spectrum cephalosporin-resistant Gram-negative bacteria in a Taiwanese university hospital. J. Antimicrob. Chemother. 49:69-76.
23. Knottnerus, B J, et al. 2008. Fosfomycin tromethamine as second agent for the treatment of acute uncomplicated urinary tract infections in adult female patients in The Netherlands? J. Antimicrob. Chemother. 62:356-359. (Pubitemid 351984780)
24. Ko, K S, et al. 2007. In vitro activity of fosfomycin against ciprofloxacin-resistant or extended-spectrum β-lactamase-producing Escherichia coli isolated from urine and blood. Diagn. Microbiol. Infect. Dis. 58:111-115.
25. Kuo, L C, et al. 2008. Antimicrobial resistance of bacterial isolates from respiratory care wards in Taiwan: A horizontal surveillance study. Int. J. Antimicrob. Agents 31:420-426.
26. Maraki, S., et al. 2009. Susceptibility of urinary tract bacteria to fosfomycin. Antimicrob. Agents Chemother. 53:4508-4510.
27. Marchese, A., L. Gualco, E A Debbia, G C Schito, and A M Schito. 2003. In vitro activity of fosfomycin against gram-negative urinary pathogens and the biological cost of fosfomycin resistance. Int. J. Antimicrob. Agents 22(Suppl. 2):53-59.
28. Martinez-Martinez, L., G. Rodriguez, A. Pascual, A I Suarez, and E J Perea. 1996. In-vitro activity of antimicrobial agent combinations against multiresistant Acinetobacter baumannii. J. Antimicrob. Chemother. 38:1107-1108. (Pubitemid 27073294)
29. Metzler, C M, and R M DeHaan. 1974. Susceptibility tests of anaerobic bacteria: Statistical and clinical considerations. J. Infect. Dis. 130:588-594.
30. Neu, H C 1990. Fosfomycin trometamol versus amoxycillin - single-dose multicenter study of urinary tract infections. Chemotherapy 36(Suppl. 1):19-23.
31. Okazaki, M., et al. 2002. Effectiveness of fosfomycin combined with other antimicrobial agents against multidrug-resistant Pseudomonas aeruginosa isolates using the efficacy time index assay. J. Infect. Chemother. 8:37-42. (Pubitemid 34456578)
32. Olay, T., A. Rodriguez, L E Oliver, M V Vicente, and M C Quecedo. 1978. Interaction of fosfomycin with other antimicrobial agents: In vitro and in vivo studies. J. Antimicrob. Chemother. 4:569-576. (Pubitemid 9053783)
33. Patel, S S, J A Balfour, and H M Bryson. 1997. Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infection. Drugs 53:637-656. (Pubitemid 27145957)
34. Rodríguez-Baño, J., et al. 2008. Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Arch. Intern. Med. 168:1897-1902.
35. Shimizu, M., et al. 2000. Novel fosfomycin resistance of Pseudomonas aeruginosa clinical isolates recovered in Japan in 1996. Antimicrob. Agents Chemother. 44:2007-2008. (Pubitemid 30422968)
36. Superti, S., C A G Dias, and P A d'Azevedo. 2009. In vitro fosfomycin activity in vancomycin-resistant Enterococcus faecalis. Braz. J. Infect. Dis. 13:123-124.
37. Tan, C K, S J Liaw, C J Yu, L J Teng, and P R Hsueh. 2008. Extensively drug-resistant Stenotrophomonas maltophilia in a tertiary care hospital in Taiwan: Microbiologic characteristics, clinical features, and outcomes. Diagn. Microbiol. Infect. Dis. 60:205-210.
38. Tessier, F, and C. Quentin. 1997. In vitro activity of fosfomycin combined with ceftazidime, imipenem, amikacin, and ciprofloxacin against Pseudomonas aeruginosa. Eur. J. Clin. Microbiol. Infect. Dis. 16:159-162. (Pubitemid 27135969)
39. Turnidge, J., G. Kahlmeter, and G. Kronvall. 2006. Statistical characterization of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values. Clin. Microbiol. Infect. 12:418-425.
40. Wachino, J-I, K. Yamane, S. Suzuki., K. Kimura, and Y. Arakawa. 2010. Prevalence of fosfomycin resistance among CTX-M-producing Escherichia coli clinical isolates in Japan and identification of novel plasmid-mediated fosfomycin-modifying enzymes. Antimicrob. Agents Chemother. 54:3061-3064.
41. Wang, J L, and P R Hsueh. 2009. Therapeutic options for infections due to vancomycin-resistant enterococci. Expert Opin. Pharmacother. 10:785-796.